Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 7/20 | 0.53 |
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSL | P07711 | 5/20 | 0.53 |
| ▸ | CTSB | P07858 | 5/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9848644 | 0.93 | CTSK (0.54) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL15381003 | 0.90 | ALDH1A1 (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL14677202 | 0.90 | CTSK (0.56) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL13724740 | 0.86 | CASP1 (0.64) | KYNUALDH1A1ALOX15CTSKCASP1 | |
| SCHEMBL1067460 | 0.86 | CASP1 (0.64) | KYNUALDH1A1ALOX15CTSKCASP1 | |
| SCHEMBL19695419 | 0.86 | CASP1 (0.64) | KYNUALDH1A1ALOX15CTSKCASP1 | |
| SCHEMBL12400686 | 0.85 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL2617394 | 0.85 | KYNU (0.62) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL345952 | 0.85 | ALDH1A1 (0.63) | KYNUALDH1A1ALOX15CTSKCTSS | |
| SCHEMBL12208731 | 0.85 | ALDH1A1 (0.63) | KYNUALDH1A1ALOX15CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100239551-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-09-23 | — | — | US | disclosed |
| US-20100239551-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-09-23 | — | — | US | disclosed |
| WO-2008097673-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239551-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS8, PRSS1, PRSS2 | KYNU 4465/4885ALDH1A1 4130/4885ALOX15 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.